Trial Profile

A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Fluorouracil (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms PELICAN

Most Recent Events

26 Jul 2024 Planned End Date changed from 30 Apr 2025 to 22 Aug 2027.
26 Jul 2024 Status changed from recruiting to active, no longer recruiting.
14 Dec 2019 Since June 2018, 7 patients have been enrolled in a single center and 13 additional centers are expected to open before the end of 2019 as per trial design presented at the 42nd Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com